Brain tumor patients get virus-immunotherapy combo in new trial

NCT ID NCT05084430

Recruiting now Disease control Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Jan 28, 2026 · Last updated May 24, 2026 · Updated 9 times

Summary

This study tests a treatment for people with aggressive brain tumors (glioblastoma, anaplastic astrocytoma, or gliosarcoma) that have come back or are newly diagnosed. The treatment combines a genetically modified herpes virus (M032) that delivers an immune-boosting protein (IL-12) with the immunotherapy drug pembrolizumab. The goal is to see if this combination is safe and can help patients live longer. About 28 participants will receive the virus injected into the tumor and pembrolizumab through an IV.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOSARCOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University of Alabama at Birmingham
RECRUITING

Birmingham, Alabama, 35294, United States

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ANAPLASTIC ASTROCYTOMA GLIOBLASTOMA MULTIFORME GLIOBLASTOMA MULTIFORME GLIOSARCOMA